Answers are grounded in this paper and cite their sources.
Narrative review reveals insufficient evidence for remdesivir efficacy in COVID-19 patients, highlighting the need for conclusive randomized trial data.
activity against SARS-CoV-2, uncontrolled clinical reports, and limited data from randomized trials. Overall, current data are insufficient to judge the efficacy of remdesivir for COVID-19, and the results of additional randomized studies are eagerly anticipated. In this narrative review, we provide an overview of Ebola and coronavirus outbreaks. We then summarize preclinical and clinical studies of remdesivir for Ebola and COVID-19.
No takes yet. Share an insight, caveat, or question.
Pardo et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: